Quest Diagnostics (NYSE:DGX) Updates FY 2025 Earnings Guidance

Quest Diagnostics (NYSE:DGX) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 9.550-9.800 for the period, compared to the consensus earnings per share estimate of 9.720. The company issued revenue guidance of $10.7 billion-$10.9 billion, compared to the consensus revenue estimate of $10.7 billion.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DGX. Robert W. Baird upgraded Quest Diagnostics from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $157.00 to $182.00 in a report on Wednesday, October 23rd. Leerink Partnrs upgraded shares of Quest Diagnostics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 6th. UBS Group increased their price objective on shares of Quest Diagnostics from $165.00 to $166.00 and gave the company a “neutral” rating in a research note on Wednesday, October 23rd. StockNews.com raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, Piper Sandler increased their target price on Quest Diagnostics from $150.00 to $165.00 and gave the company a “neutral” rating in a research report on Monday, October 28th. Six analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $172.15.

Quest Diagnostics Stock Down 1.2 %

DGX stock opened at $155.32 on Thursday. The company has a quick ratio of 1.17, a current ratio of 1.25 and a debt-to-equity ratio of 0.83. Quest Diagnostics has a 52 week low of $123.04 and a 52 week high of $165.32. The stock has a market capitalization of $17.34 billion, a PE ratio of 20.88, a price-to-earnings-growth ratio of 2.36 and a beta of 0.90. The firm has a 50 day moving average of $155.54 and a 200 day moving average of $153.42.

Quest Diagnostics Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 29th. Stockholders of record on Tuesday, January 14th were issued a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.93%. The ex-dividend date was Tuesday, January 14th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 40.32%.

Insider Buying and Selling

In other Quest Diagnostics news, CAO Michael J. Deppe sold 18,755 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $154.05, for a total transaction of $2,889,207.75. Following the completion of the transaction, the chief accounting officer now directly owns 34,941 shares of the company’s stock, valued at approximately $5,382,661.05. This trade represents a 34.93 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.79% of the stock is currently owned by company insiders.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.